PSNL News and Press, Personalis Inc. From 05/06/21

Analysts weigh in on potential of COVID-19 patent waiversYesterday's announcement that the U.S. would support a waiver of IP protections for COVID-19 vaccines led to a slide in vaccine makers.However, several analysts believe the potential impact may be overhyped as other countries also oppos...

Stealth BioTherapeutics (MITO) +58% after showcases data for Elamipretide.Luokung Technology Corp. (LKCO) +22% on announcing favorable ruling granting preliminary injunction.Nemaura Medical (NMRD) +23% on 200K sugarBEAT sensors order.American Shared Hospital Services (AMS) +28%...

Personalis, Inc. (PSNL) Q1 2021 Earnings Conference Call May 05, 2021 05:00 PM ET Company Participants Caroline Corner - IR John West - President and CEO Aaron Tachibana - CFO Conference Call Participants Doug Schenkel - Cowen Vidyun Bais - BTIG Mike Matson - Needham & Company Swayampakul...

Personalis (PSNL): Q1 GAAP EPS of -$0.29 beats by $0.07.Revenue of $20.88M (+9.0% Y/Y) beats by $0.45M.Press Release For further details see: Personalis EPS beats by $0.07, beats on revenue

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the first quarter ended March 31, 2021. First Quarter Highlights Record quarterly revenue of $20.9 million in the first quarter of 2021...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 2021 Bank of America Healthcare Conference on Thursday, May 13, 2021 at 5:00 p.m. Eastern Time. About Personalis, Inc. Personalis, Inc. is ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its first quarter 2021 financial results after the market closes on Wednesday, May 5, 2021. In conjunction with the release, the Company will host a conference call and webcast tha...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held online, April 10-15, 202...

Personalis (PSNL) announces a collaboration with MapKure to use a clinical trial assay ((CTA)) based on the Personalis NeXT Platform to support development of BGB-3245 in patients with advanced or refractory solid tumors.MapKure is a clinical-stage company focusing on genetically defined...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a collaboration with MapKure, LLC, a clinical-stage company focusing on genetically defined disease drivers and jointly owned by BeiGene, Ltd. and SpringWorks Therapeutics, Inc., to use a clinical...